June 5, 2024
LungLife AI, Inc. ("LungLife" or the "Company") Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll. Full details of the voting will be available […]
• Read MoreMay 15, 2024
LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: Name of applicant: LungLife AI, Inc. […]
• Read MoreApril 25, 2024
LungLife AI, Inc.(the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now available on the Company’s […]
• Read MoreApril 17, 2024
LungLife AI, Inc.(the “Company” or “LungLife”) LungLife to present at US National Cancer Institute’s Early Detection Research Network Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces it has been invited to present at the National Cancer Institute’s (“NCI”) Early Detection Research Network (“EDRN”) meeting […]
• Read MoreApril 4, 2024
LungLife AI, Inc.(the “Company” or “LungLife”) Preliminary audited results for year ended 31 December 2023 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its audited preliminary results for the year ended 31 December 2023. Summary and Highlights for the year and post-period end: Commenting, Paul Pagano, Chief Executive Officer […]
• Read MoreMarch 27, 2024
LungLife AI Inc (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2023 on Thursday 4 April 2024. Investor presentation Paul Pagano, Chief Executive Officer, and David Anderson, Chief Financial […]
• Read MoreMarch 22, 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN […]
• Read More
LungLife AI licensure/accreditation information posted here.